Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1 25Phase 1/2 24Phase 3 5Phase NA 2Phase EARLY_PHASE1 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Carcinoma, Renal Cell 3Melanoma 2Kidney Neoplasms 2Solid Tumors 1Solid Tumor 1Skin Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Nivolumab 9pembrolizumab 6Ipilimumab 5Magnetic Resonance Spectroscopy 3resiquimod 2encorafenib 2binimetinib 2aldesleukin 2Oncolytic Virotherapy 2MART-1 Antigen 2Interleukin-2 2Cyclophosphamide 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1fludarabine phosphate 1fludarabine 1durvalumab 1clevudine 1cemiplimab 1avelumab 1Specimen Handling 1Sentinel Lymph Node Biopsy 1S 28463 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Melanoma × Interleukin-2 × Clear all
NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT00276835 2015-04-10

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

Northwestern University

Phase EARLY_PHASE1 Completed
15 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡